These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37726835)

  • 21. Metastasic Prostate Cancer: Predictive Factors of Earlier Progression to Castration-Resistance.
    Dellavedova T; Malizia E; Quinteros L; Nobile R; Minuzzi F
    Arch Esp Urol; 2022 Jun; 75(5):430-434. PubMed ID: 35983814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of maintenance of the common androgen deprivation therapy with the new antiandrogen therapy in patients with castration-resistant prostate cancer: a systematic review.
    Salgado CM; Garcia-Perdomo HA; Reis LO
    Int Urol Nephrol; 2022 Jun; 54(6):1187-1192. PubMed ID: 35384583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral heterogeneity and genetic characteristics of prostate cancer.
    Wu B; Lu X; Shen H; Yuan X; Wang X; Yin N; Sun L; Shen P; Hu C; Jiang H; Wang D
    Int J Cancer; 2020 Jun; 146(12):3369-3378. PubMed ID: 32159858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
    World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
    Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy.
    Lee CU; Cho E; Lee J; Lim JE; Chung JH; Song W; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Eur Urol Focus; 2023 Jan; 9(1):89-95. PubMed ID: 36167777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
    Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
    Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
    Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
    Brown NE; Jones A; Hunt BG; Waltz SE
    Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
    Huang FM; Li XH; Liang Y
    Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
    Huang H; Chen S; Li W; Bai P; Wu X; Xing J
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.].
    Valencia-Guadalajara VJ; Martínez-Cayuelas L; Sarrió-Sanz P; Sánchez-Caballero L; Polo-Hernández R; Chillón-Sempere FS; Galán-Llopis JA; Garcés-Valverde M; Tenza-Tenza JA; Costa-Martínez A; García Serrado-Paumard D; Escudero-Fontana E; Tello-Royloa C; Verdú-Verdú LP; Bravo-López DF; Pérez Seoane-Ballester H; Pacheco-Bru JJ; Ortiz-Gorraiz MÁ
    Arch Esp Urol; 2020 Jul; 73(6):499-508. PubMed ID: 32633245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.